Neparvis

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

sacubitril, valsartan

Available from:

Novartis Europharm Limited

ATC code:

C09DX04

INN (International Name):

sacubitril, valsartan

Therapeutic group:

Aġenti li jaġixxu fuq is-sistema renin-angiotensin

Therapeutic area:

Insuffiċjenza tal-Qalb

Therapeutic indications:

Paediatric heart failureNeparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. Adult heart failureNeparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.

Product summary:

Revision: 18

Authorization status:

Awtorizzat

Authorization date:

2016-05-26

Patient Information leaflet

                                _ _
77
B. FULJETT TA’ TAGĦRIF
_ _
78
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-PAZJENT
Neparvis 24 MG/26 MG PILLOLI MIKSIJA B’RITA
Neparvis 49 MG/51 MG PILLOLI MIKSIJA B’RITA
Neparvis 97 MG/103 MG PILLOLI MIKSIJA B’RITA
sacubitril/valsartan
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib, lill-ispiżjar jew
lill-infermier tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anke jekk għandhom l-istess sinjali ta’
mard bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT:
1.
X’inhu Neparvis u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Neparvis
3.
Kif għandek tieħu Neparvis
4.
Effetti sekondarji possibbli
5.
Kif taħżen Neparvis
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU NEPARVIS U GĦALXIEX JINTUŻA
Neparvis huwa mediċina tal-qalb li fiha inibitur ta’ neprilysin
ta’ riċettur tal-anġjotensina. Huwa
jwassal żewġ sustanzi attivi, sacubitril u valsartan.
Neparvis jintuża biex jittratta tip ta’ insuffiċjenza tal-qalb
fit-tul fl-adulti, fit-tfal u fl-adolexxenti (ta’
sena u ikbar).
Din it-tip ta’ insuffiċjenza tal-qalb isseħħ meta l-qalb tkun
dgħajfa u ma tkunx tista’ tippompja
biżżejjed demm fil-pulmuni u fil-bqija tal-ġisem. L-aktar sintomi
komuni ta’ insuffiċjenza tal-qalb
huma qtugħ ta’ nifs, letarġija, għeja u nefħa fl-għaksa.
_ _
79
2.
X’GĦANDEK TKUN TAF QABEL MA TIEĦU NEPARVIS
TIĦUX NEPARVIS
•
jekk inti allerġiku għal sacubitril, valsartan jew għal xi sustanza
oħra ta’ din il-mediċina
(imniżżla fis-sezzjoni 6).
•
jekk qed tieħu xi tip ieħor ta’ mediċina msejħa inibitur ta’
enzima t
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
_ _
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Neparvis 24 mg/26 mg pilloli miksija b’rita
Neparvis 49 mg/51 mg pilloli miksija b’rita
Neparvis 97 mg/103 mg pilloli miksija b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Neparvis 24 mg/26 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 24.3 mg sacubitril u 25.7 mg
valsartan (bħala kumpless ta’ melħ tas-
sodju sacubitril valsartan).
Neparvis 49 mg/51 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 48.6 mg sacubitril u 51.4 mg
valsartan (bħala kumpless ta’ melħ tas-
sodju sacubitril valsartan).
Neparvis 97 mg/103 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 97.2 mg sacubitril u 102.8 mg
valsartan (bħala kumpless ta’ melħ tas-
sodju sacubitril valsartan).
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita (pillola)
Neparvis 24 mg/26 mg pilloli miksija b’rita
Pillola miksija b’rita ta’ għamla mżaqqa u ovali u ta’ lewn
vjola u abjad bi ġnub tasturati, mingħajr
sinjali dritti, imnaqqxa b’“NVR” fuq naħa waħda u “LZ” fuq
in-naħa l-oħra. Id-dimensjonijiet
approssimattivi tal-pillola huma ta’ 13.1 mm x 5.2 mm.
Neparvis 49 mg/51 mg pilloli miksija b’rita
Pillola miksija b’rita ta’ għamla mżaqqa u ovali u ta’ lewn
isfar pallidu bi ġnub tasturati, mingħajr
sinjali dritti, imnaqqxa b’“NVR” fuq naħa waħda u “L1” fuq
in-naħa l-oħra. Id-dimensjonijiet
approssimattivi tal-pillola huma ta’ 13.1 mm x 5.2 mm.
Neparvis 97 mg/103 mg pilloli miksija b’rita
Pillola miksija b’rita ta’ għamla mżaqqa u ovali u ta’ lewn
roża ċar bi ġnub tasturati, mingħajr sinjali
dritti, imnaqqxa b’“NVR” fuq naħa waħda u “L11” fuq
in-naħa l-oħra. Id-dimensjonijiet
approssimattivi tal-pillola huma ta’ 15.1 mm x 6.0 mm.
_ _
3
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Insuffiċjenza tal-qalb fl-adulti
Neparvis huwa indikat f’pazjenti adulti għat-trat
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 21-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 21-03-2024
Public Assessment Report Public Assessment Report Bulgarian 22-06-2023
Patient Information leaflet Patient Information leaflet Spanish 21-03-2024
Public Assessment Report Public Assessment Report Spanish 22-06-2023
Patient Information leaflet Patient Information leaflet Czech 21-03-2024
Public Assessment Report Public Assessment Report Czech 22-06-2023
Patient Information leaflet Patient Information leaflet Danish 21-03-2024
Public Assessment Report Public Assessment Report Danish 22-06-2023
Patient Information leaflet Patient Information leaflet German 21-03-2024
Public Assessment Report Public Assessment Report German 22-06-2023
Patient Information leaflet Patient Information leaflet Estonian 21-03-2024
Public Assessment Report Public Assessment Report Estonian 22-06-2023
Patient Information leaflet Patient Information leaflet Greek 21-03-2024
Public Assessment Report Public Assessment Report Greek 22-06-2023
Patient Information leaflet Patient Information leaflet English 21-03-2024
Public Assessment Report Public Assessment Report English 22-06-2023
Patient Information leaflet Patient Information leaflet French 21-03-2024
Public Assessment Report Public Assessment Report French 22-06-2023
Patient Information leaflet Patient Information leaflet Italian 21-03-2024
Public Assessment Report Public Assessment Report Italian 22-06-2023
Patient Information leaflet Patient Information leaflet Latvian 21-03-2024
Public Assessment Report Public Assessment Report Latvian 22-06-2023
Patient Information leaflet Patient Information leaflet Lithuanian 21-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 21-03-2024
Public Assessment Report Public Assessment Report Lithuanian 22-06-2023
Patient Information leaflet Patient Information leaflet Hungarian 21-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 21-03-2024
Public Assessment Report Public Assessment Report Hungarian 22-06-2023
Patient Information leaflet Patient Information leaflet Dutch 21-03-2024
Public Assessment Report Public Assessment Report Dutch 22-06-2023
Patient Information leaflet Patient Information leaflet Polish 21-03-2024
Public Assessment Report Public Assessment Report Polish 22-06-2023
Patient Information leaflet Patient Information leaflet Portuguese 21-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 21-03-2024
Public Assessment Report Public Assessment Report Portuguese 22-06-2023
Patient Information leaflet Patient Information leaflet Romanian 21-03-2024
Public Assessment Report Public Assessment Report Romanian 22-06-2023
Patient Information leaflet Patient Information leaflet Slovak 21-03-2024
Public Assessment Report Public Assessment Report Slovak 22-06-2023
Patient Information leaflet Patient Information leaflet Slovenian 21-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 21-03-2024
Public Assessment Report Public Assessment Report Slovenian 22-06-2023
Patient Information leaflet Patient Information leaflet Finnish 21-03-2024
Public Assessment Report Public Assessment Report Finnish 22-06-2023
Patient Information leaflet Patient Information leaflet Swedish 21-03-2024
Public Assessment Report Public Assessment Report Swedish 22-06-2023
Patient Information leaflet Patient Information leaflet Norwegian 21-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 21-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 21-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 21-03-2024
Patient Information leaflet Patient Information leaflet Croatian 21-03-2024
Public Assessment Report Public Assessment Report Croatian 22-06-2023

Search alerts related to this product

View documents history